Patents by Inventor Ming Yu
Ming Yu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20260269615Abstract: The present discloses a linear time-periodic model of a three-level inverter considering neutral point dynamics. In the present application, a piecewise linearization processing method is adopted to divide non-differentiable terms in an original nonlinear model of a three-level inverter into a plurality of linear segments, and linearization processing is carried out in each segment to eliminate the non-differentiable terms of a non-differentiable part (such as a neutral point voltage and a neutral point current) and ensure that the linear time-periodic model of a three-level inverter obtained is locally analyzable, which avoids the problem of difficulty in overall linearization. The linear time-periodic model of a three-level inverter is generated by combining with a steady-state trajectory, which can comprehensively reflect small signal characteristics of a three-level inverter. This model can be applied to small-signal stability analysis of power systems containing a three-level inverter.Type: ApplicationFiled: January 5, 2026Publication date: September 10, 2026Applicants: Guangxi Power Grid Co. LTD, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGYInventors: Hui Qin, Jiabing Hu, Juan Chen, Jiali Kui, Ming Yu, Yingbiao Li, Zhen Pan, Guojie Zhao, Xin Lin, Zhaolin Zhang, Junjie Feng, Zefei Wu, Buyang Du, Zeren Guo
-
Publication number: 20260199227Abstract: The present invention relates to an injectable formulation, a method for treating a metabolic disease and an administration device. The injectable formulation comprises a lipid matrix composition, a specific amount of a GLP-1 receptor agonist and at least one pharmaceutically acceptable ion. Accordingly, upon contacting an aqueous fluid, the injectable formulation forms a depot exhibiting an extended release of the GLP-1 receptor agonist in vivo or in vitro. In the method for treating the metabolic disease, the injectable formulation can be administered to a subject with a reduced dosing frequency, and it is not necessary to store the injectable formulation for the next administration. For the administration device, the injectable formulation is filled in a vial, a pre-filled syringe or a pre-filled cartridge. Therefore, the injectable formulation can be designed for a single use, thereby enhancing convenience, compliance and adherence of a subject.Type: ApplicationFiled: December 23, 2025Publication date: July 16, 2026Inventors: Ming YU, Ming-Hong HSU, Wei Fan LIN, Pen Chung CHEN
-
Publication number: 20260167848Abstract: Thermoplastic primer compositions may include a high surface energy thermoplastic resin having a surface energy of 37 dynes/cm or greater, at a percent by weight (wt %) of 55 wt % to 90 wt %; a low surface energy thermoplastic resin having a surface energy of less than 37 dynes/cm, at 10 wt % to 45 wt %; wherein the thermoplastic primer composition has a glass transition temperature in the range of 60° C. to 120° C. Multilayer compositions may include a substrate having a surface energy of 37 dynes/cm or greater; a primer layer containing a thermoplastic primer composition; and one or more thermoset adhesive layers.Type: ApplicationFiled: November 21, 2022Publication date: June 18, 2026Inventors: Yongchun Chen, Qingwei Meng, Guo Zeng, Jiguang Zhang, Ming Yu, Yang Liu, Qi Gao, Shouxue Guo, Yi Zhang, Shaoguang Feng
-
Patent number: 12626364Abstract: The present disclosure provides materials and methods related to image processing. In particular, the present disclosure provides methods for enhancing target signal detection using imaging processing analysis that identifies and removes non-specific background signals. The image processing methods of the present disclosure are useful for enhancing target signals in a variety of assays that involve fluorescent detection (e.g., fluorescent in situ hybridization, immunofluorescence).Type: GrantFiled: April 15, 2022Date of Patent: May 12, 2026Assignee: Advanced Cell Diagnostics, Inc.Inventors: Ching-Wei Chang, Xiao-Jun Ma, Han Lu, Bing-Qing Zhang, HaYeun Ji, Ming Yu
-
Publication number: 20260118848Abstract: Teachings of the present disclosure include methods, apparatus, electronic devices, and medium for marking an operating parameter. An example method includes: acquiring a three-dimensional image sequence of a spindle motion process of a machine tool, the three-dimensional image sequence captured by an imaging component; creating an operating parameter curve representing the spindle motion process; recognizing a spindle motion mode from the three-dimensional image sequence; determining time information of the spindle motion mode; and marking the operating parameter curve based on the time information and motion description information associated with the spindle motion mode.Type: ApplicationFiled: January 13, 2023Publication date: April 30, 2026Applicant: Siemens AktiengesellschaftInventors: Ming Yu, Qi Wang, Yue Hua Zhang, De Yu Tian
-
Patent number: 12585361Abstract: Input devices can employ ultrasonic touch sensing capabilities that allow user inputs to be detected through conductive materials, such as metal enclosures. The ultrasonic touch sensing can include generation of ultrasound signals with a piezoelectric layer. The ultrasound signals can be reflected when a user or other object is in contact with a housing, and the reflected signal can be detected by the same piezoelectric layer that produced the ultrasound signal. Such a piezoelectric layer can include a piezoelectric polymer, such as polyvinylidene fluoride (PVDF). An array of electrodes distributed on opposing sides of the use of electric layer can be operated to generate ultrasound signals and detect reflected signals. Such an input device can be operated in conjunction with a conductive (e.g., metallic) housing, conform to a variety of shapes, and be compact and lightweight.Type: GrantFiled: September 27, 2022Date of Patent: March 24, 2026Assignee: Apple Inc.Inventors: Qiliang Xu, Ming Yu, Xiaonan Wen, Ehsan Khajeh, Jason S. Griesbach, Brian M. King
-
Publication number: 20260078091Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.Type: ApplicationFiled: March 4, 2025Publication date: March 19, 2026Inventors: Michael D. Bartberger, Ana Gonzalez Buenrostro, Hilary Plake Beck, Xiaoqi Chen, Richard Victor Connors, Jeffrey Deignan, Jason A. Duquette, I, John Eksterowicz, Benjamin Fisher, Brian M. Fox, Jiasheng Fu, Zice Fu, Felix Gonzalez Lopez De Turiso, Michael W. Gribble, Darin J. Gustin, Julie A. Heath, Xin Huang, XianYun Jiao, Michael G. Johnson, Frank Kayser, David John Kopecky, SuJen Lai, Yihong Li, Zhihong Li, Jiwen Liu, Jonathan D. Low, Brian S. Lucas, Zhihua MA, Lawrence R. McGee, Joel McIntosh, Dustin L. McMinn, Julio C. Medina, Jeffrey Thomas Mihalic, Steven H. Olson, Yossup Rew, Philip M. Roveto, Daqing Sun, Xiaodong Wang, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu
-
Patent number: 12513573Abstract: The present disclosure relates to a network resource request method. An example method includes obtaining network intent information of a user, where the network intent information includes quantity information of a terminal device and service requirement information of the terminal device. The example method further includes performing classification representation on the network intent information based on an intent model, where the intent model includes a terminal device set, a service flow set, and a mapping relationship between the terminal device set and the service flow set. The example method further includes generating service level agreement (SLA) information based on a representation result of the intent model and sending the SLA information to an element management system.Type: GrantFiled: June 21, 2023Date of Patent: December 30, 2025Assignee: Huawei Technologies Co., LTD.Inventors: Fengbao Wang, Shanshan Wang, Ming Yu, Jun Yang
-
Publication number: 20250274731Abstract: The present disclosure relates to information processing methods and devices. In one example method, a first device obtains first information, where the first information indicates an intent, and the first device processes the intent based on second information, where the second information indicates an operation on the intent. In other words, after the first device determines the intent for the communication network, the first device processes the intent, based on the operation on the intent, to implement network operation and maintenance based on the intent.Type: ApplicationFiled: May 9, 2025Publication date: August 28, 2025Inventors: Ming YU, Weijian ZHOU, Shanshan WANG, Yongjun YANG, Lingliang SHUAI, Zhi PENG
-
Publication number: 20250215502Abstract: Methods and kits to distinguish normal or Barrett's esophageal samples from high grade dysplasia (HGD), esophageal adenocarcinoma (EAC), or junctional adenocarcinoma (JCA) samples are described. The methods and kits utilize the methylation status of epigenetic markers, such as cg6522, POU3F1, YPEL3, and/or MAFB.Type: ApplicationFiled: March 8, 2023Publication date: July 3, 2025Applicant: Fred Hutchinson Cancer CenterInventors: William M. Grady, Ming Yu, Amber Willbanks
-
Patent number: 12324845Abstract: A method of imaging, the method comprising administering, to a subject, a compound of Structure Alpha, of the formula: or a pharmaceutically acceptable salt thereof, wherein: n is 0; R, R1, and R3 are independently selected from the group consisting of H, OR4, F, Cl, Br, I, CF3, alkyl (C1-C4), aryl, heteroaryl, C(?O)R4, CO2R4, N(R4)2, CN, C(?NR4)OR5, NR4C(?NR5)NHR6, C(?NR4)NHR5, C(?O)NHR4, NR4C(?O)NR5, NR4NR5, SO2OR4, and imaging moiety Im; R2 is absent; R4, R5, and R6 are independently selected from the group consisting of H, alkyl, aryl and heteroaryl substituents; wherein the alkyl, aryl, or heteroaryl may be substituted with imaging moiety Im, wherein optionally any two of R4, R5, and R6 form a cyclic structure selected from the group consisting of —CH2—CH2—, —CH2—CH2—CH2, —CH?CH—, —X?CH—, and —X—CH?CH—, wherein X is selected from the group consisting of O, NH, and NR7, and wherein R7 is selected from the group consisting of alkyl, aryl, and heteroaryl substituents; W, X, Y and Z are independently sType: GrantFiled: January 28, 2022Date of Patent: June 10, 2025Assignee: Lantheus Medical Imaging, Inc.Inventors: Ajay Purohit, Thomas D. Harris, Heike S. Radeke, Simon P. Robinson, Ming Yu, David S. Casebier, Michael T. Azure
-
Publication number: 20250170282Abstract: The present invention relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in 18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs. In some embodiments, methods and compositions for assessing perfusion and innervation mismatch in a portion of a subject are provided.Type: ApplicationFiled: January 17, 2025Publication date: May 29, 2025Applicant: Lantheus Medical Imaging, Inc.Inventors: Heike S. Radeke, Richard R. Cesati, Ajay Purohit, Thomas D. Harris, Simon P. Robinson, Ming Yu, David S. Casebier, Carol Hui Hu, Matthias Broekema, David C. Onthank
-
Publication number: 20250161500Abstract: Novel compounds that find use as imaging agents within nuclear medicine applications (PET imaging) for imaging of cardiac innervation are disclosed. These PET based radiotracers may exhibit increased stability, decreased NE release (thereby reducing side effects), improved quantitative data, and/or high affinity for VMAT over prior radiotracers. Methods of using the compounds to image cardiac innervation are also provided. In some instances the compounds are developed by derivatizing certain compounds with 18F in a variety of positions: aryl, alkyl, a keto, benzylic, beta-alkylethers, gamma-propylalkylethers and beta-proplylalkylethers. Alternatively or additionally, a methyl group a is added to the amine, and/or the catechol functionality is either eliminated or masked as a way of making these compounds more stable.Type: ApplicationFiled: January 17, 2025Publication date: May 22, 2025Applicant: Lantheus Medical Imaging, Inc.Inventors: Ajay Purohit, Thomas D. Harris, Heike S. Radeke, Simon P. Robinson, Ming Yu, David S. Casebier, Michael T. Azure
-
Patent number: 12299476Abstract: A method for detecting a processor comprises: determining a parameter stored in a first-type register in a detected processor, which is used to detect changes in the data processed by the detected processor, wherein the parameter relates to the a number of the data that needs to be processed currently by the detected processor, and relates to the a processing mode of the data that needs to be processed currently by the detected processor which can be characterized by using information of instructions or functions called during processing; determining a working state of the detected processor based on the parameter, and performing an interrupt missing handling operation if the working state is a first type of working state being an interrupt missing state. The method can conveniently and reliably realize the detection of interrupt loss, thereby effectively monitoring the situation of interrupt loss.Type: GrantFiled: June 10, 2021Date of Patent: May 13, 2025Assignee: HORIZON (SHANGHAI) ARTIFICIAL INTELLIGENCE TECHNOLOGY CO., LTD.Inventors: Ming Yu, Xiaofeng Ling
-
Publication number: 20250031988Abstract: A method and system for extracting a target signal based on maximum correlated kurtosis deconvolution are provided, which relate to a field of signal processing. The method includes: obtaining a microwave signal of a brain of a subject to be tested; filtering the microwave signal by using maximum correlated kurtosis deconvolution to obtain a filtered signal; performing mode decomposition on the filtered signal by using a complete ensemble empirical mode decomposition with adaptive noise to obtain a target response signal; and performing image reconstruction on the target response signal by using a delay sum beamforming to obtain a target bleeding image.Type: ApplicationFiled: July 27, 2023Publication date: January 30, 2025Inventors: Ming Yu, Qinwei Li, Feng Chen, Hang Wu, Guang Zhang
-
Publication number: 20250026763Abstract: Provided herein are compounds having an amide-based backbone that is connected to multiple ring structures, pharmaceutically acceptable salts of the compounds, pharmaceutical compositions thereof, and method of use thereof as selective allosteric inhibitors of EGFR mutants.Type: ApplicationFiled: May 24, 2024Publication date: January 23, 2025Inventors: Ming YU, Yipin LU, Dai CHENG, Fang LI, Lina GU, Tiansheng WANG
-
Patent number: 12168447Abstract: A method for information processing, a device, and a computer readable storage medium are provided. The method includes the following. At an in-vehicle electronic device, in response to a determination that a received voice input is associated with switching a source device for switching a rendered content shown at the in-vehicle electronic device, voiceprint information of the voice input is obtained. A user identity corresponding to the voiceprint information is identified. A mapping table between user identities and connected electronic devices or connectable electronic devices is searched for a first electronic device corresponding to the identified user identity. In response to searching out the first electronic device, a first channel for transmission of rendered content between the in-vehicle electronic device and the first electronic device is established, so as to render a first presenting content which is received from the first electronic device through the first channel.Type: GrantFiled: July 8, 2022Date of Patent: December 17, 2024Assignee: Shanghai Qwik Smart Technology Co., Ltd.Inventors: Zhenkai Ying, Hongren Shi, Ming Yu
-
Publication number: 20240411564Abstract: Disclosed are a memory-partition-based device-startup method and apparatus, a computer readable storage medium, and an electronic device. The method includes: determining a boot status of an electronic device in a first boot mode at a preset occasion; reading, based on the boot status, first boot information from a first partition of a target memory; booting the electronic device in a second boot mode based on the first boot information, and acquiring system update information for the electronic device from a system update server; updating, based on the system update information, second boot information in a second partition of the target memory; and booting the electronic device in the first boot mode based on the updated second boot information.Type: ApplicationFiled: April 11, 2024Publication date: December 12, 2024Applicant: BEIJING HORIZON INFORMATION TECHNOLOGY CO., LTD.Inventors: Ming YU, Xiaofeng LING
-
Publication number: 20240408107Abstract: The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.Type: ApplicationFiled: October 5, 2022Publication date: December 12, 2024Applicant: Global Blood Therapeutics, Inc.Inventors: Shahul Nilar, Lina Q. Setti, Chul Yu, Ming Yu
-
Publication number: 20240300892Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.Type: ApplicationFiled: October 11, 2023Publication date: September 12, 2024Inventors: Michael D. Bartberger, Ana Gonzalez Buenrostro, Hilary Plake Beck, Xiaoqi Chen, Richard Victor Connors, Jeffrey Deignan, Jason A. Duquette, I, John Eksterowicz, Benjamin Fisher, Brian M. Fox, Jiasheng Fu, Zice Fu, Felix Gonzalez Lopez De Turiso, Michael W. Gribble, Darin J. Gustin, Julie A. Heath, Xin Huang, XianYun Jiao, Michael G. Johnson, Frank Kayser, David John Kopecky, SuJen Lai, Yihong Li, Zhihong Li, Jiwen Liu, Jonathan D. Low, Brian S. Lucas, Zhihua MA, Lawrence R. McGee, Joel McIntosh, Dustin L. McMinn, Julio C. Medina, Jeffrey Thomas Mihalic, Steven H. Olson, Yossup Rew, Philip M. Roveto, Daqing Sun, Xiaodong Wang, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu